In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Remote ischaemic conditioning does not improve outcomes in patients with heart attack

CONDI-2/ERIC-PPCI trial presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Heart Failure


Paris, France – 1 Sept 2019: Remote ischaemic conditioning does not reduce mortality or heart failure at one year in patients with myocardial infarction, according to late breaking results from the CONDI-2/ERIC-PPCI study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology (1) .

Co-principal investigator Professor Hans Erik Bøtker of Aarhus University Hospital, Denmark, said: “Although declining in Europe, acute myocardial infarction remains a leading cause of death worldwide. The introduction of prompt and effective treatment with immediate balloon dilatation has reduced the death rate but this decline has reached a plateau and the appearance of subsequent heart failure has not decreased according to expectations. New methods to reduce the damage on the heart and improve clinical outcome are needed.”

Previous studies have shown that remote ischaemic condition can reduce infarct size (the area of damaged heart tissue) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) but until now its effect on clinical outcomes was unknown.

Remote ischaemic conditioning is an experimental procedure not currently used in clinical practice. It aims to protect organs or tissue against ischaemia-reperfusion injury. This injury can occur when tissue is exposed to lack of blood flow due to a blocked artery (ischaemia) and subsequently reperfused when the artery is opened using balloon dilatation with stent implantation or blood clot dissolving drugs. Ischaemia-reperfusion injuries are seen in the heart during myocardial infarction and in the brain during stroke.

The remote ischaemic conditioning procedure involves repeated, temporary (i.e. five minutes) cessation of blood flow to a limb to intermittently stop and restore blood flow to the limb. The procedure can be done with a blood pressure cuff or an automatic pressure cuff device. This "conditioning" activates the body's natural protective physiology against tissue damage in a remote organ.

This study examined whether remote ischaemic conditioning could reduce cardiac death and rehospitalisation for heart failure at one year in 5,401 STEMI patients treated with primary PCI. (2) To enhance robustness of the study, two trial organisations (CONDI-2 and ERIC-PPCI) were merged, enabling the researchers to recruit patients at 33 centres in four countries (Denmark, Serbia, Spain, and the UK).

Patients were randomly allocated to standard treatment plus remote ischaemic conditioning or standard treatment alone. Remote ischaemic conditioning was performed either in the ambulance or on hospital admission. It was done with four cycles of five minutes inflation and five minutes deflation using an automatic pressure cuff on the right upper arm such that blood flow to the arm was intermittently stopped and restored.

Standard treatment on arrival at the hospital was opening the artery using balloon dilatation and stent implantation according to current guidelines including relevant antithrombotic therapy. (3) Successful restoration of blood flow was achieved in more than 95% of patients.

Patients were followed-up for one year for the composite primary endpoint of cardiac death or admission for heart failure. The overall event rate for the primary endpoint was low, at 8.9% after 12 months. The event rate did not differ between the group receiving standard treatment (8.6%) and the group also receiving remote ischaemic conditioning (9.4%) (hazard ratio, 1.10; 95% confidence interval, 0.91 to 1.32; p=0.32).

There were no differences between groups in the occurrence of secondary endpoints, which were the combined outcome of cardiac death and hospitalisation for heart failure at 30 days and major adverse cardiovascular and cerebral events at 30 days and one year.

No differences in outcomes between groups were observed in prespecified subgroup analyses according to age, diabetic status, infarction location, Thrombolysis In Myocardial Infarction (TIMI) flow, and time elapsed from first medical contact to balloon time

Professor Bøtker and co-principal investigator, Professor Derek Hausenloy of University College London, UK agreed that: “Remote ischaemic conditioning does not seem to be the way to further improve outcome in patients with acute myocardial infarction undergoing immediate revascularisation with balloon dilatation and stent implantation. Although the neutral outcome is disappointing, the result is robust because the findings were consistent across trial organisations and the study included a large number of patients to ensure adequate power for a definitive answer.”

ENDS

Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding: The ERIC-PPCI trial was funded by a British Heart Foundation Clinical Study Grant (CS/14/3/31002) and a University College London Hospital/University College London Biomedical Research Clinical Research grant. The CONDI-2 trial was funded by Danish Innovation Foundation grants (11-108354 and 11-115818), Novo Nordisk Foundation (NNF13OC0007447), and Trygfonden (109624).

Disclosures: Hans Erik Bøtker is a shareholder in CellAegis Inc. Derek Hausenloy has no disclosures to report. 

References and notes

(1) CONDI-2/ERIC-PPCI will be discussed during:

(2) Hausenloy DJ, Kharbanda R, Rahbek Schmidt M, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2015;36:1846–1848. doi:10.1093/eurheartj/ehv249.

(3) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119–177. doi: 10.1093/eurheartj/ehx393.

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.